Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/P	го		c	omplete if Known	
11150	DIATION	DIO	N OOUDE	Application Number	10/587,652	
	RMATION			Filing Date	09-29-06	
STA	rement b	SY AP	PLICANT	First Named Inventor	Jean-Hilaire Saurat	
				Art Unit	1616	
	(Use as many she	ets as ne	cessary)	Examiner Name	L. Karpinski	
Sheet	1	of	2	Attorney Docket Number	3493-0175PUS1	$\overline{}$

	U.S. PATENT DOCUMENTS							
Examiner initial *	Cite	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines. Where			
initiai "	No.	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	3.4							
	***************************************							
					****			
					1			
			**************************************					
	***************************************							
		100000000000000000000000000000000000000						
	***************************************							
			1					

		FOREIG	N PATENT DOC	UMENTS		
Examiner initial *	Cite No. 1	Foreign Patent Document  Country <sup>3</sup> Number <sup>4</sup> Kind Code (if known) <sup>5</sup> Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	
000000000000000000000000000000000000000	0000000000	02/D000000064040404040200000000000000000000	02-10-1020	000000000000000000000000000000000000000	000000000000000000000000000000000000000	墂
***************************************						۱'n
	·					늗
	·					止
						Ц
					1	
						Г

Examiner Signature	/Luke Karpinski/	Date Considered	03/07/2012

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation design number (optional). 2 See Kinds Codes of USPTO patent Documents, at www.uspto.gov or MPEP 901.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449B/PTO			Ce	omplete if Known
INFOR	MATION D	וכרו	OSLIDE	Application Number	10/587,652
	STATEMENT BY APPLICANT				09-29-06
SIAIL		AFF	LICANI	First Named Inventor	Jean-Hilaire Saurat
(U:	se as many sheets a	s neces	sarv)	Art Unit	1616
, ,			<b>3</b> ,	Examiner Name	L. Karpinski
Sheet	2	of	2	Attorney Docket Number	3493-0175PUS1

Examiner initial * Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Caecade, F.J. et al., "LMW Hydraenie Acid to Induse Epidermal Regeneration", Brug & Oosmetie Industry, 148(3), pp. 30, 32, 34 and 74, (March 1991).  Japanese Office Action dated May31, 2011  Keizumi, H. "Special Review/Astivation of Chin Celle and Geometic Development Keratinization Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).  Thelan, L. et al., "Encapsulation Technologies Applied to Retinoids, a Way to Modulate Bise vallebility and Reactivity", Fragrance Journal, 29(2), pp. 83-90, (2001).		NON PATENT LITERATURE DOCUMENTS						
2 Industry, 148(3), pp. 30, 32, 34 and 74, (March 1991).  lapanese Office Action dated May 21, 2011  3 Keizumi, H. "Special Review Activation of Skin Cells and Commetic Development Keretinization  4 Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).  Thelen, Latal, "Encapsulation Technologies Applied to Retinaids, a Way to Medulate Bioweilebility.				item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T 2			
2 Industry, 148(3), pp. 30, 32, 34 and 74, (March 1991).  lapanese Office Action dated May 21, 2011  3 Keizumi, H. "Special Review Activation of Skin Cells and Commetic Development Keretinization  4 Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).  Thelen, Latal, "Encapsulation Technologies Applied to Retinaids, a Way to Medulate Bioweilebility.	000000000000000000000000000000000000000		000000000000000000000000000000000000000	Casado-F-U-ot at will WW Hyakeronic Acid to Induce Epidermal Regeneration Progress Commetic	000000000			
3  Koizumi, H. "Special Review/Activation of Skin Colle and Coemetic Development Koratinization 4 Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).  Tholon, L. ot al., "Encapsulation Technologies Applied to Retinoids, a Way to Modulate Bisavailability.			2	Industry, 148(3), pp. 30, 32, 34 and 74, (March 1991).				
Keizumi, H., "Special Review/Activation of Skin Colle and Seemetic Development Keratinization 4 Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).  Thelen, L. et al., "Encapsulation Technologies Applied to Retinoids, a Way to Modulate Bioavailability.	000000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000	Inpanese Office Action dated May 21, 2011.	000000000			
Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).  Thelen, L. et al., "Encapsulation Technologies Applied to Retinoids, a Way to Modulate Bioavailability.			3					
Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).  Thelen, L. et al., "Encapsulation Technologies Applied to Retinoids, a Way to Modulate Bioavailability.	***************************************	000000000000000000000000000000000000000	0000000000000	KeizumiH"Special Review/Activation of Skin Colleged Scometic Development Keratinjzgion	0000000000			
			4	Disorders and Retinoids", Fragrance Journal, 20(2), pp. 26-31, (1992).	Γ			
	000000000000000000000000000000000000000	>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	000000000000000000000000000000000000000	Thelen, Letal "Encapsulation Technologies Asslied to Retinaide a Way to Madulate Biografichility	0000000000			
			5					
		The state of the s						
	;	No. and the second seco						

Signature Considered Considered		Examiner Signature	/Luke Karpinski/	Date Considered	03/07/2012
---------------------------------	--	-----------------------	------------------	--------------------	------------

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.